SCHEDULE 13G/A: Wellington Management Group Discloses 8.19% Passive Stake in Kymera Therapeutics

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.19% in Kymera Therapeutics, Inc. as of December 31, 2024.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively reported beneficial ownership of 5,307,326 shares of Kymera Therapeutics, Inc. common stock.
• This aggregate beneficial ownership represents 8.19% of the total outstanding common stock of Kymera Therapeutics, Inc.
• The filing indicates that the shares are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of the issuer.
• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each reported shared voting power over 4,903,040 shares and shared dispositive power over 5,307,326 shares.
• Wellington Management Company LLP reported shared voting power over 4,900,791 shares and shared dispositive power over 5,170,216 shares.
• No single client of Wellington Management Group is known to have the right to receive or direct the receipt of dividends or proceeds from the sale of more than five percent of this class of securities.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the issuer's performance or prospects. It simply reports a passive stake.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This Schedule 13G filing indicates a substantial passive investment by a major institutional asset manager, Wellington Management, in Kymera Therapeutics, Inc., a biotechnology company. Such filings are common for large investment firms managing diverse portfolios and reflect their holdings in publicly traded companies within the biotechnology sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which can influence market perception and liquidity.

Key Dates

Keywords

Kymera Therapeutics, Wellington Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Investment Management